# Transcutaneous Supraorbital Nerve Stimulator Versus Topiramate in Prevention of Recurrent Migraine

> **NCT05516251** · NA · UNKNOWN · sponsor: **Tongji Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Migraine, Classic

## Interventions

- **DEVICE:** Transcutaneous Supraorbital Nerve Stimulator
- **DRUG:** Topiramate 25Mg Tab

## Key facts

- **NCT ID:** NCT05516251
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05516251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05516251, "Transcutaneous Supraorbital Nerve Stimulator Versus Topiramate in Prevention of Recurrent Migraine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05516251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*